Cytori Therapeutics (CYTX) Updates on Several, Recently-Issued Patents
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Cytori Therapeutics, Inc. (Nasdaq: CYTX) announced the issuance of a number of key patents that strengthen its intellectual property portfolio in the U.S. and Europe. Cytori now has over 90 global patents issued and another 55 patent applications pending around the globe. Several of Cytori’s recently-issued patents contain claims providing protections for Cytori’s program in the use of Cytori Cell Therapy™ for treating scleroderma. Cytori recently completed enrollment in its STAR approval trial in the US for this indication.
On November 1, 2016, US Patent No. 9480718 was issued. This patent contains claims applying to the use of adipose derived cells to treat peripheral vascular diseases (“PVD”), which are blood circulation disorders that affect the blood carrying vessels of the body that can narrow, experience spasm or become blocked. PVD is often a contributory process in scleroderma. This patent has term at least through 2022 and claims the use of Cytori Cell Therapy™ for PVD, including but not limited to PVD associated with scleroderma.
On November 8, 2016, US Patent No. 9486484 was issued. This patent provides protections around the use of adipose-derived cells for the treatment of edema. Edema, also known as ‘swelling’, is often accompanied by increased blood flow and is a very common secondary clinical manifestation of numerous inflammatory and immune-related conditions. Specifically, edema contributes directly to the diminished hand dysfunction found often in the acute phases of scleroderma. The ‘484 patent term lasts through at least 2029.
Other recently issued patents strengthen Cytori’s osteoarthritis program. Last month, US Patent No. 9463203 was issued. The ‘203 patent protects the use of adipose-derived cells for treating cartilage defects, including but not limited to osteoarthritic defects, defects in the articular cartilage and defects in meniscus. Earlier this year, Cytori completed the ACT-OA clinical trial, a phase IIb trial assessing the use of adipose-derived cells for the treatment of osteoarthritis of the knee. The ‘203 patent term lasts through at least 2022.
The European Patent Office also recently issued European Patent No. EP2617427 to Cytori. The ‘427 Patent protects the use of adipose-derived cells for restoring tears in cartilage such as those present in osteoarthritic joints, and has a patent term at least through 2024.
On November 15, 2016 US Patent No. 9492483 was issued. The ‘483 Patent relates to the use of adipose-derived regenerative cells for the treatment of burn, and area in which Cytori has had an active research program for several years in conjunction with the US Government. The ‘483 patent term lasts at least through December 2022.
“Cytori has amassed a large global intellectual property position and continues to expand and strengthen the portfolio through internal R&D efforts and targeted in-licensing,” noted John D. Harris, Vice President and General Manager, Cell Therapy. “The recent patents specifically serve to support our current development efforts in scleroderma, osteoarthritis, and burn.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb (BMY), Ono Enter Settlement and License Agreement with Merck (MRK) to Resolve PD-1 Antibody Patent Litigation
- Valhi, Inc. (VHI) Names Robert D. Graham as President and CEO
- Bioptix (BIOP) to Terminate Some Employees Associated with Acquisition of its Subsidiary
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!